13 recruiting, 4 active not recruiting, 2 completed, 2 terminated. 23 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Recruiting 13, Active not recruiting 4, Completed 2, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Recruiting 8, Active not recruiting 1, Completed 1, Unknown 1 |
Follow Mixed Phenotype Acute Leukemia: new trials by email Literature Review of Mixed Phenotype Acute Leukemia trials Research Report on Mixed Phenotype Acute Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT ORCA-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Recruiting | Stanford University | 24 | 2025-12-01 | 2026-06-23 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia | Phase 1 | Active not recruiting | Fred Hutchinson Cancer Center | 30 | 2023-12-18 | 2026-07-29 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-10-30 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | PedAL BCU, LLC | 960 | 2022-04-18 | 2026-08-25 |
| Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL MRX-2843 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Meryx, Inc. | 50 | 2022-04-01 | 2026-01-08 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-11-06 |
| Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia Humanized CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2021-06-01 | 2021-06-02 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation revumenib, cobicistat - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Syndax Pharmaceuticals | 447 | 2019-11-05 | 2026-10-09 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Vorinostat, Azacitidine Injection - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Johns Hopkins All Children's Hospital | 15 | 2019-05-01 | 2026-07-15 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies OrcaGraft (Orca-Q) - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Recruiting | Orca Biosystems, Inc. | 300 | 2019-04-08 | 2026-09-29 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (23) · Leukemia, Myeloid, Acute (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Myelodysplastic Syndromes (7) · Leukemia (6) · Hematologic Neoplasms (3) · Leukemia, Myelomonocytic, Chronic (3) · Leukemia, Myelomonocytic, Juvenile (3) · Anemia, Refractory, with Excess of Blasts (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Blast Crisis (1)
Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Immune System Diseases (23) · Immunoproliferative Disorders (23) · Leukemia, Lymphoid (23) · Lymphatic Diseases (23) · Lymphoproliferative Disorders (23) · Neoplasms (23) · Neoplasms by Histologic Type (23) · Leukemia, Myeloid (19) · Leukemia (17) · Bone Marrow Diseases (10) · Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6)
Cytarabine (6) · Specimen Handling (5) · Biopsy (4) · revumenib (4) · Granulocyte Colony-Stimulating Factor (3) · Methotrexate (3) · X-Rays (3) · fludarabine (3) · Azacitidine (2) · Calcium Dobesilate (2) · Cladribine (2) · Decitabine (2) · Dexamethasone (2) · Filgrastim (2) · Hydrocortisone (2)
Fred Hutchinson Cancer Center (5) · Syndax Pharmaceuticals (2) · Children's Oncology Group (1) · Ehab L Atallah (1) · Johns Hopkins All Children's Hospital (1) · Kura Oncology, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · Meryx, Inc. (1) · OHSU Knight Cancer Institute (1) · Orca Biosystems, Inc. (1) · PedAL BCU, LLC (1) · Roncarolo, Maria Grazia, MD (1) · Stanford University (1) · The First Affiliated Hospital of Soochow University (1) · Therapeutic Advances in Childhood Leukemia Consortium (1)
United States (21) · Canada (4) · Australia (3) · France (2) · Germany (2) · Italy (2) · Puerto Rico (2) · Spain (2) · Belgium (1) · China (1) · Israel (1) · Lithuania (1) · Netherlands (1) · New Zealand (1)
Adam Lamble, MD (1) · Angela R Smith, M.D. (1) · Ben K Watkins (1) · Brenda M. Sandmaier (1) · Cassandra Josephson, MD (1) · Ehab L Atallah, MD (1) · Elizabeth Krakow (1) · Jacob Appelbaum, MD, PhD (1) · James S McClellan, MD, PhD (1) · Jessica T Leonard (1) · Jordan Milner, MD (1) · Joshua Zeidner, MD (1) · Kuo-Kai Chin, MD (1) · Lori Muffly (1) · Mary-Beth M. Percival (1)
PMID 33741715, PMID 34267079, PMID 30335787, PMID 32077361, PMID 36175988, PMID 36922593, PMID 38683966, PMID 39121437, PMID 39170618, PMID 39362248, PMID 40332046, PMID 40535475, PMID 40997296, PMID 41621809
P01CA049605 (1), P01CA078902 (1), P30CA015704 (1), U10CA180886 (1), UM1CA228823 (1)